

# Pioneering systems biology in clinical microbicide trials – MTN-007 and beyond


**Florian Hladik**  
[www.hlab.science](http://www.hlab.science)





# The ever interesting story of tenofovir gel

- I. Immunological effects of tenofovir gel**
- II. Potential longer-term effects and how to study them**
- III. Hypothetical ramifications beyond the microbicide field**

# MTN-007 study design



# MTN-007 rectal biopsies yielded excellent RNA quality and quantity




n=381


# Number of genes changing expression after 7 days of treatment

	Up	Down
Nonoxynol-9	60	56
Tenofovir	137	505
HEC	12	4
No treatment	17	6


Consensus data across 8 study subjects




# Tenofovir inhibits the anti-inflammatory arm of gut immunity



# Confirmation by immunohistology





Rectal biopsies  
in MTN-007




# Do the immunological effects of tenofovir gel also occur in the genital tract?


- Will be investigated in MTN-014, a vaginal-rectal cross-over study of 1% tenofovir gel
- Was investigated *in vitro* with primary vaginal epithelial cells established from four healthy women







# IL-10 in vaginal epithelial cells




Olszak T et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. *Nature* 22;509:497-502 (2014)

# The immunological effects of tenofovir are complex


- Tenofovir is an immune modulator rather than stimulator in the mucosa  
**(“anti-anti-inflammatory”)**
- The consequences of this property on HIV susceptibility remain unclear, but ongoing studies in CAPRISA 004 subjects suggest that in the presence of inflammation they may become clinically relevant (Jo-Ann Passmore)

## II. Potential longer-term effects and how to study them

# Tenofovir increases epithelial cell proliferation ...




... and generally enhances cell viability



# Tenofovir causes mitochondrial dysfunction

## Mitochondrial ATP6 gene suppression



# AZT, another NRTI, was highly carcinogenic in topical rodent studies

## Incidence of Vaginal Histopathologic Findings in Mice Given Zidovudine Intravaginally      (*n = 50 / arm*)

Finding	Concentration (mg/ml)			
	EC	VC	5	20
Squamous cell carcinoma	0	0	2	13
Epithelial dysplasia	0	0	1	6

*Note.* EC, environmental control; VC, vehicle control.

Ayers KM et al.

Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats.

*Fundamental & Applied Toxicology* 32:148-58 (1996)

**Thus, carcinogenicity assessment of topical microbicides could be important, but is difficult**

**NIH/NIAID R01 AI116292 (05/01/15 – 04/30/20)**

**Systems and Carcinogenic Impact Assessment of Topical Microbicides on the Human Mucosa**


- Systems studies: MTN-014 and MTN-017**
- Carcinogenicity screening models**

# Carcinogenicity screening of microbicides


## HISTORIC STANDARD MOUSE CARCINOGENICITY STUDY (excessively expensive)<sup>9</sup>



## PROPOSED MOUSE CARCINOGENICITY STUDY




## PROPOSED HUMAN CELL CARCINOGENICITY STUDY



### **III. Hypothetical ramifications beyond the microbicide field**

# Hypothesized effects of NRTIs on HIV latency



Saavedra-Lozano et al.  
3TC and ABC decrease  
p24 production from  
HIV-infected resting  
T cells after activation  
*J Virology* 48:2825-2830 (2004)

Hladik F.  
A new hypothesis on HIV cure  
*bioRxiv* (2014)  
*F1000Research* (2015)

# **Disclaimer**

**There is as yet no clinical evidence  
whatsoever for NRTI carcinogenicity  
or latency-prolonging effects**

# Acknowledgements

**Ian McGowan  
(MTN-007)**

**Julie McElrath  
(Fred Hutch)**

**Craig Hendrix  
(Johns Hopkins)**

**NIH / NIAID (MIG)  
NICHD / NIMH**

**Lamar Fleming  
Sean Hughes (Fred Hutch)**

**Adam Burgener  
Blake Ball (Manitoba)**

**Raphael Gottardo  
(Fred Hutch)**

**Study Participants  
& Clinic Staff  
MTN-007 Investigators**